Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004)

Detalhes bibliográficos
Autor(a) principal: Gales, Ana Cristina [UNIFESP]
Data de Publicação: 2006
Outros Autores: Jones, R. N., Sader, Helio Silva [UNIFESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://dx.doi.org/10.1111/j.1469-0691.2005.01351.x
http://repositorio.unifesp.br/handle/11600/28802
Resumo: In total, 54 731 Gram-negative bacilli isolated worldwide between 2001 and 2004 from diverse sites of infection were tested for susceptibility to polymyxin B by the broth reference microdilution method, with interpretation of results according to CLSI (formerly NCCLS) guidelines. Polymyxin B showed excellent potency and spectrum against 8705 Pseudomonas aeruginosa and 2621 Acinetobacter spp. isolates (MIC50, <= 1 mg/L and MIC90, 2 mg/L for both pathogens). Polymyxin B resistance rates were slightly higher for carbapenem-resistant P. aeruginosa (2.7%) and Acinetobacter spp. (2.8%), or multidrug-resistant (MDR) P. aeruginosa (3.3%) and Acinetobacter spp. (3.2%), when compared with the entire group (1.3% for P. aeruginosa and 2.1% for Acinetobacter spp.). Among P. aeruginosa, polymyxin B resistance rates varied from 2.9% in the Asia-Pacific region to only 1.1% in Europe, Latin America and North America, while polymyxin B resistance rates ranged from 2.7% in Europe to 1.7% in North America and Latin America among Acinetobacter spp. Polymyxin B also demonstrated excellent activity (MIC90, <= 1 mg/L; > 98% susceptible) against Citrobacter spp., Escherichia coli and Klebsiella spp., but activity was more variable against Enterobacter spp. (MIC50, <= 1 mg/L; 83.3% susceptible) and Stenotrophomonas maltophilia (MIC50, <= 1 mg/L; 72.4% susceptible), and was very limited (MIC50, > 8 mg/L) against Burkholderia cepacia (11.8% susceptible), Serratia spp. (5.4% susceptible), indole-positive Proteus spp. (1.3% susceptible) and Proteus mirabilis (0.7% susceptible).
id UFSP_c66b252bbc0ca2983be772acb840a823
oai_identifier_str oai:repositorio.unifesp.br/:11600/28802
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004)antimicrobial activityGram-negative bacillipolymyxin BresistanceSENTRYsurveillanceIn total, 54 731 Gram-negative bacilli isolated worldwide between 2001 and 2004 from diverse sites of infection were tested for susceptibility to polymyxin B by the broth reference microdilution method, with interpretation of results according to CLSI (formerly NCCLS) guidelines. Polymyxin B showed excellent potency and spectrum against 8705 Pseudomonas aeruginosa and 2621 Acinetobacter spp. isolates (MIC50, <= 1 mg/L and MIC90, 2 mg/L for both pathogens). Polymyxin B resistance rates were slightly higher for carbapenem-resistant P. aeruginosa (2.7%) and Acinetobacter spp. (2.8%), or multidrug-resistant (MDR) P. aeruginosa (3.3%) and Acinetobacter spp. (3.2%), when compared with the entire group (1.3% for P. aeruginosa and 2.1% for Acinetobacter spp.). Among P. aeruginosa, polymyxin B resistance rates varied from 2.9% in the Asia-Pacific region to only 1.1% in Europe, Latin America and North America, while polymyxin B resistance rates ranged from 2.7% in Europe to 1.7% in North America and Latin America among Acinetobacter spp. Polymyxin B also demonstrated excellent activity (MIC90, <= 1 mg/L; > 98% susceptible) against Citrobacter spp., Escherichia coli and Klebsiella spp., but activity was more variable against Enterobacter spp. (MIC50, <= 1 mg/L; 83.3% susceptible) and Stenotrophomonas maltophilia (MIC50, <= 1 mg/L; 72.4% susceptible), and was very limited (MIC50, > 8 mg/L) against Burkholderia cepacia (11.8% susceptible), Serratia spp. (5.4% susceptible), indole-positive Proteus spp. (1.3% susceptible) and Proteus mirabilis (0.7% susceptible).Universidade Federal de São Paulo, Div Infect Dis, BR-04025010 São Paulo, BrazilJMI Labs, N Liberty, IA USATufts Univ, Sch Med, Boston, MA 02111 USAUniversidade Federal de São Paulo, Div Infect Dis, BR-04025010 São Paulo, BrazilWeb of ScienceBlackwell PublishingUniversidade Federal de São Paulo (UNIFESP)JMI LabsTufts UnivGales, Ana Cristina [UNIFESP]Jones, R. N.Sader, Helio Silva [UNIFESP]2016-01-24T12:41:03Z2016-01-24T12:41:03Z2006-04-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion315-321application/pdfhttp://dx.doi.org/10.1111/j.1469-0691.2005.01351.xClinical Microbiology and Infection. Oxford: Blackwell Publishing, v. 12, n. 4, p. 315-321, 2006.10.1111/j.1469-0691.2005.01351.xWOS000235661400004.pdf1198-743Xhttp://repositorio.unifesp.br/handle/11600/28802WOS:000235661400004engClinical Microbiology and Infectioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-07T07:52:50Zoai:repositorio.unifesp.br/:11600/28802Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-07T07:52:50Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004)
title Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004)
spellingShingle Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004)
Gales, Ana Cristina [UNIFESP]
antimicrobial activity
Gram-negative bacilli
polymyxin B
resistance
SENTRY
surveillance
title_short Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004)
title_full Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004)
title_fullStr Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004)
title_full_unstemmed Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004)
title_sort Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004)
author Gales, Ana Cristina [UNIFESP]
author_facet Gales, Ana Cristina [UNIFESP]
Jones, R. N.
Sader, Helio Silva [UNIFESP]
author_role author
author2 Jones, R. N.
Sader, Helio Silva [UNIFESP]
author2_role author
author
dc.contributor.none.fl_str_mv Universidade Federal de São Paulo (UNIFESP)
JMI Labs
Tufts Univ
dc.contributor.author.fl_str_mv Gales, Ana Cristina [UNIFESP]
Jones, R. N.
Sader, Helio Silva [UNIFESP]
dc.subject.por.fl_str_mv antimicrobial activity
Gram-negative bacilli
polymyxin B
resistance
SENTRY
surveillance
topic antimicrobial activity
Gram-negative bacilli
polymyxin B
resistance
SENTRY
surveillance
description In total, 54 731 Gram-negative bacilli isolated worldwide between 2001 and 2004 from diverse sites of infection were tested for susceptibility to polymyxin B by the broth reference microdilution method, with interpretation of results according to CLSI (formerly NCCLS) guidelines. Polymyxin B showed excellent potency and spectrum against 8705 Pseudomonas aeruginosa and 2621 Acinetobacter spp. isolates (MIC50, <= 1 mg/L and MIC90, 2 mg/L for both pathogens). Polymyxin B resistance rates were slightly higher for carbapenem-resistant P. aeruginosa (2.7%) and Acinetobacter spp. (2.8%), or multidrug-resistant (MDR) P. aeruginosa (3.3%) and Acinetobacter spp. (3.2%), when compared with the entire group (1.3% for P. aeruginosa and 2.1% for Acinetobacter spp.). Among P. aeruginosa, polymyxin B resistance rates varied from 2.9% in the Asia-Pacific region to only 1.1% in Europe, Latin America and North America, while polymyxin B resistance rates ranged from 2.7% in Europe to 1.7% in North America and Latin America among Acinetobacter spp. Polymyxin B also demonstrated excellent activity (MIC90, <= 1 mg/L; > 98% susceptible) against Citrobacter spp., Escherichia coli and Klebsiella spp., but activity was more variable against Enterobacter spp. (MIC50, <= 1 mg/L; 83.3% susceptible) and Stenotrophomonas maltophilia (MIC50, <= 1 mg/L; 72.4% susceptible), and was very limited (MIC50, > 8 mg/L) against Burkholderia cepacia (11.8% susceptible), Serratia spp. (5.4% susceptible), indole-positive Proteus spp. (1.3% susceptible) and Proteus mirabilis (0.7% susceptible).
publishDate 2006
dc.date.none.fl_str_mv 2006-04-01
2016-01-24T12:41:03Z
2016-01-24T12:41:03Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1111/j.1469-0691.2005.01351.x
Clinical Microbiology and Infection. Oxford: Blackwell Publishing, v. 12, n. 4, p. 315-321, 2006.
10.1111/j.1469-0691.2005.01351.x
WOS000235661400004.pdf
1198-743X
http://repositorio.unifesp.br/handle/11600/28802
WOS:000235661400004
url http://dx.doi.org/10.1111/j.1469-0691.2005.01351.x
http://repositorio.unifesp.br/handle/11600/28802
identifier_str_mv Clinical Microbiology and Infection. Oxford: Blackwell Publishing, v. 12, n. 4, p. 315-321, 2006.
10.1111/j.1469-0691.2005.01351.x
WOS000235661400004.pdf
1198-743X
WOS:000235661400004
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Clinical Microbiology and Infection
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 315-321
application/pdf
dc.publisher.none.fl_str_mv Blackwell Publishing
publisher.none.fl_str_mv Blackwell Publishing
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268376765169664